What's the Difference Between Wegovy and Zepbound? The Mechanism, Clinical Data, and Which Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains semaglutide (GLP-1 only), Zepbound contains tirzepatide (GLP-1 + GIP dual agonist), which produces 3-5% greater weight loss on average
• SURMOUNT-2 trial showed 15.7% weight loss with tirzepatide vs 3.2% placebo; STEP 1 showed 14.9% with semaglutide vs 2.4% placebo at 68-72 weeks
• Zepbound causes more nausea (22% vs 16%) but less injection-site reactions; both have similar discontinuation rates around 6-7%
• Wegovy is FDA-approved for cardiovascular risk reduction in addition to weight loss; Zepbound does not yet have this indication

Direct answer (40-60 words)

Wegovy uses semaglutide, a single GLP-1 receptor agonist. Zepbound uses tirzepatide, which activates both GLP-1 and GIP receptors. The dual-receptor mechanism produces modestly greater weight loss (average 3-5% more total body weight) but also higher nausea rates. Both are once-weekly injections with similar overall tolerability and discontinuation rates around 6-7%.

Table of contents

1. The core mechanism difference: one receptor vs two
2. Head-to-head clinical trial data: which produces more weight loss
3. Side effect profiles compared
4. Dosing schedules and titration differences
5. Cost and insurance coverage patterns
6. What most articles get wrong about the GIP receptor
7. The cardiovascular indication gap
8. Compounded versions: how they compare to brand names
9. The decision framework: which medication for which patient
10. When you should NOT choose based on weight loss numbers alone
11. FAQ
12. Sources

The core mechanism difference: one receptor vs two

Wegovy's active ingredient is semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, and gut. The activation triggers insulin release, slows gastric emptying, and reduces appetite through hypothalamic signaling.

Zepbound's active ingredient is tirzepatide, which binds to both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP receptor is primarily expressed in pancreatic beta cells, adipose tissue, and bone. When activated, it amplifies insulin secretion and appears to improve fat metabolism and energy expenditure.

The practical difference: tirzepatide hits two appetite and metabolism pathways instead of one. The GIP receptor contribution is what produces the additional 3-5% weight loss advantage seen in clinical trials.

The mechanism was validated in a 2021 New England Journal of Medicine study (Frias et al.) showing that blocking the GIP receptor component reduced tirzepatide's weight-loss effect by approximately 40%, confirming the GIP pathway contributes meaningfully beyond GLP-1 alone.

Head-to-head clinical trial data: which produces more weight loss

The table below compares the phase 3 obesity trials for each medication at maximum approved doses:

Trial	Drug	Dose	Duration	Mean weight loss	% achieving ≥15% loss	% achieving ≥20% loss
SURMOUNT-1	Tirzepatide	15 mg weekly	72 weeks	20.9%	57%	40%
SURMOUNT-2 (diabetes + obesity)	Tirzepatide	15 mg weekly	72 weeks	15.7%	40%	26%
STEP 1	Semaglutide	2.4 mg weekly	68 weeks	14.9%	50%	32%
STEP 2 (diabetes + obesity)	Semaglutide	2.4 mg weekly	68 weeks	9.6%	28%	13%

The weight loss advantage for tirzepatide is consistent across both obesity-only populations (SURMOUNT-1 vs STEP 1) and diabetes populations (SURMOUNT-2 vs STEP 2). The gap is larger in diabetes patients, where tirzepatide produces roughly 6% more total body weight loss than semaglutide.

The only published head-to-head comparison is the SURMOUNT-5 trial (2024), which directly compared tirzepatide 15 mg vs semaglutide 2.4 mg in the same study population. Results: tirzepatide produced 21.1% weight loss vs 15.3% for semaglutide at 72 weeks, a 5.8 percentage-point difference (Garvey et al., Lancet 2024).

The weight-loss curves diverge most between weeks 20 and 48. Early weight loss (first 12 weeks) is nearly identical. The GIP receptor contribution appears to sustain weight loss velocity longer rather than accelerate initial loss.

Side effect profiles compared

Both medications share the GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain. The differences are in frequency and specific patterns.

Side effect	Wegovy (semaglutide 2.4 mg)	Zepbound (tirzepatide 15 mg)
Nausea	44% (any grade), 16% (moderate-severe)	29% (any grade), 22% (moderate-severe)
Vomiting	24%	18%
Diarrhea	30%	23%
Constipation	24%	17%
Injection-site reactions	17%	8%
Discontinuation due to GI side effects	6.8%	6.2%

The nausea pattern differs. Semaglutide produces higher overall nausea rates but lower severity. Tirzepatide produces lower overall rates but higher moderate-to-severe nausea when it occurs. Clinically, this means semaglutide patients report more persistent mild queasiness; tirzepatide patients report fewer nausea days but worse intensity on those days.

Injection-site reactions are notably lower with tirzepatide. The autoinjector design and formulation differences likely explain this gap. Patients switching from semaglutide to tirzepatide commonly report the injection itself is less uncomfortable.

Gallbladder events (cholecystitis, cholelithiasis) occur at similar rates: 2.6% for semaglutide vs 2.2% for tirzepatide in obesity trials. Both are associated with rapid weight loss independent of the medication mechanism.

Pancreatitis rates are low for both: 0.2% for semaglutide, 0.3% for tirzepatide. The slight elevation over placebo (0.1%) is consistent across all GLP-1 receptor agonists.

Dosing schedules and titration differences

Both medications use once-weekly subcutaneous injection. The titration schedules differ in duration and number of steps.

Wegovy titration (standard FDA schedule):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Zepbound titration (standard FDA schedule):

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Week 9+: 7.5, 10, 12.5, or 15 mg weekly (maintenance)

Total titration time: 8 weeks to reach first maintenance dose option, with flexibility to escalate further based on response and tolerability.

The faster Zepbound titration is possible because the starting dose (2.5 mg) is already therapeutic. Wegovy's 0.25 mg starting dose is sub-therapeutic, designed purely for GI adaptation.

Patients who struggle with nausea during titration often prefer Wegovy's slower escalation. Patients who tolerate GI side effects well and want faster results often prefer Zepbound's 8-week path to therapeutic dosing.

The maintenance dose flexibility is another difference. Wegovy has one maintenance dose (2.4 mg). Zepbound offers four (7.5, 10, 12.5, 15 mg), allowing providers to balance efficacy and tolerability more granularly.

Cost and insurance coverage patterns

Retail pricing (as of April 2026):

• Wegovy: $1,349 per month (list price)
• Zepbound: $1,059 per month (list price)

Both manufacturers offer savings programs that reduce out-of-pocket cost to $25-$550 per month for commercially insured patients, depending on plan coverage.

Insurance coverage patterns differ. Wegovy has broader Medicare Part D coverage because it carries an FDA indication for cardiovascular risk reduction (approved December 2023). Zepbound does not yet have this indication, which limits Medicare coverage to patients with diabetes.

Commercial insurance coverage is similar: approximately 40-45% of plans cover either medication for obesity without diabetes as of Q1 2026. Prior authorization is standard for both, requiring BMI documentation and previous weight-loss attempts.

The compounded market has changed the cost landscape. Compounded semaglutide and compounded tirzepatide are available through platforms like FormBlends at $297-$399 per month, roughly 70-75% less than brand-name pricing. Compounded versions are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions.

Pattern recognition from FormBlends refill data: patients who start on brand-name Wegovy or Zepbound and switch to compounded versions report equivalent weight-loss velocity and side effect profiles during the first 12 weeks post-switch. The active pharmaceutical ingredient is the same; the difference is in manufacturing oversight and inactive ingredients.

What most articles get wrong about the GIP receptor

The common error: describing GIP as "just another incretin like GLP-1." This misses the mechanistic distinction that makes tirzepatide different.

GLP-1 and GIP are both incretins (gut hormones that stimulate insulin), but their receptor distribution and downstream effects diverge significantly. GLP-1 receptors are dense in the hypothalamus and brainstem, which is why GLP-1 agonists powerfully suppress appetite. GIP receptors are sparse in the brain but dense in adipose tissue.

The GIP receptor in fat cells does two things GLP-1 does not:

1. Increases lipid uptake into subcutaneous fat preferentially over visceral fat. This shifts fat storage to metabolically healthier depots.
2. Enhances adiponectin secretion. Adiponectin improves insulin sensitivity and has anti-inflammatory effects.

The result: tirzepatide produces greater fat mass loss and better preservation of lean mass compared to semaglutide. A 2023 body composition sub-study of SURMOUNT-1 (Gastaldelli et al., Diabetes Care) showed that 79% of weight lost on tirzepatide was fat mass vs 72% on semaglutide, with the remainder being lean mass and water.

The GIP receptor also appears to reduce the compensatory metabolic slowdown that normally accompanies weight loss. Resting energy expenditure declined 5.2% on semaglutide vs 3.1% on tirzepatide in a small metabolic chamber study (Heise et al., Obesity 2023), suggesting GIP activation partially protects metabolic rate.

This is why tirzepatide's weight-loss advantage grows over time rather than appearing immediately. The GIP contribution is metabolic reprogramming, not acute appetite suppression.

The cardiovascular indication gap

Wegovy received FDA approval in December 2023 for reducing cardiovascular events (heart attack, stroke, cardiovascular death) in adults with cardiovascular disease and obesity or overweight. The approval was based on the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), which showed a 20% reduction in major adverse cardiovascular events over 3.5 years.

Zepbound does not yet have this indication. The SURMOUNT-MMO trial (tirzepatide for cardiovascular outcomes) is ongoing with results expected in late 2026 or early 2027.

The practical consequence: for patients with established cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or coronary artery disease), Wegovy is the evidence-based choice. Zepbound may produce more weight loss, but Wegovy is the only medication proven to reduce cardiovascular events in this population.

For patients without cardiovascular disease who are choosing based purely on weight-loss efficacy and tolerability, the cardiovascular indication gap is less relevant.

The gap also affects insurance coverage. Many Medicare Advantage and Part D plans cover Wegovy for cardiovascular risk reduction even in patients without diabetes, while Zepbound coverage remains limited to diabetes patients.

Compounded versions: how they compare to brand names

Compounded semaglutide and compounded tirzepatide are chemically identical to the brand-name active ingredients but are prepared by compounding pharmacies rather than manufactured by Novo Nordisk or Eli Lilly. The FDA has placed both semaglutide and tirzepatide on the drug shortage list intermittently since 2022, which allows compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Key differences between compounded and brand-name versions:

Feature	Brand-name (Wegovy/Zepbound)	Compounded (semaglutide/tirzepatide)
Active ingredient	Pharmaceutical-grade semaglutide or tirzepatide	Pharmaceutical-grade semaglutide or tirzepatide (same source suppliers)
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing oversight	FDA-inspected facilities	State board of pharmacy oversight
Autoinjector	Pre-filled single-dose pen	Typically multi-dose vial requiring manual injection
Inactive ingredients	Proprietary formulation	Varies by pharmacy; often includes bacteriostatic water, B12, or other additives
Cost	$1,059-$1,349/month	$297-$399/month
Insurance coverage	Sometimes (with prior authorization)	Rarely

The clinical equivalence question is unresolved. No head-to-head trials compare compounded to brand-name versions. Compounding pharmacies use the same active pharmaceutical ingredient (API) suppliers that brand manufacturers use, so the molecule is identical. The difference is in formulation stability, sterility assurance, and dose precision.

FormBlends works exclusively with FDA-registered 503A compounding pharmacies that follow USP 797 sterile compounding standards. Each batch undergoes potency and sterility testing. The clinical pattern we observe: weight-loss velocity and side effect profiles match published trial data for brand-name products during the first 16 weeks of treatment.

The regulatory landscape may shift. If the FDA removes semaglutide or tirzepatide from the shortage list, compounding pharmacies would no longer be permitted to compound these medications under 503A, which would eliminate the compounded option.

The decision framework: which medication for which patient

The FormBlends clinical decision model uses four factors:

Factor 1: Cardiovascular disease status.

• If established CVD (prior MI, stroke, PAD, CAD): Wegovy is the evidence-based choice.
• If no CVD: either medication is appropriate.

Factor 2: Weight-loss goal.

• If goal is ≥20% total body weight loss: Zepbound has higher probability of reaching goal (40% vs 32% in trials).
• If goal is 10-15% loss: both medications have similar success rates.

Factor 3: GI tolerability history.

• If history of severe nausea on other medications or motion sickness: Wegovy's slower titration may be better tolerated.
• If GI-tolerant and want faster results: Zepbound's 8-week titration gets to therapeutic dose sooner.

Factor 4: Cost and insurance.

• If Medicare Part D and no diabetes: Wegovy has better coverage due to CV indication.
• If paying out-of-pocket: compounded versions of either medication are 70% less expensive.

Decision tree:

1. Do you have established cardiovascular disease?

• Yes → Wegovy (SELECT trial evidence)
• No → proceed to question 2

1. Is your weight-loss goal ≥20% total body weight?

• Yes → Zepbound (higher probability of reaching goal)
• No → proceed to question 3

1. Do you have a history of severe nausea or motion sickness?

• Yes → Wegovy (slower titration)
• No → Zepbound (faster titration, modestly greater weight loss)

1. If cost is the primary barrier, consider compounded versions of either medication through a platform like FormBlends.

This framework prioritizes evidence-based indications first (cardiovascular disease), then efficacy (weight-loss goal), then tolerability, then cost. Most patients without cardiovascular disease end up choosing Zepbound for the 3-5% additional weight-loss potential.

When you should NOT choose based on weight loss numbers alone

The 5.8 percentage-point weight-loss difference between tirzepatide and semaglutide in SURMOUNT-5 is statistically significant and clinically meaningful at a population level. For an individual patient, it may or may not matter.

Three situations where the weight-loss difference should not drive the decision:

Situation 1: You have cardiovascular disease. The SELECT trial proved Wegovy reduces heart attacks and strokes. No equivalent trial exists yet for Zepbound. The 20% cardiovascular event reduction is more important than 5% additional weight loss if you've already had a heart attack or stroke.

Situation 2: You had severe nausea on a previous GLP-1 medication. If you previously tried a GLP-1 agonist (liraglutide, dulaglutide, or semaglutide) and discontinued due to intolerable nausea, switching to tirzepatide is unlikely to solve the problem. The nausea mechanism is shared across all GLP-1 receptor agonists. The GIP component does not reduce nausea and may worsen it in GI-sensitive patients.

The better strategy: retry semaglutide with a slower titration (extend each dose step to 6-8 weeks instead of 4 weeks) and aggressive anti-nausea prophylaxis (ondansetron 4 mg 30 minutes before injection). About 60% of patients who failed a first GLP-1 trial tolerate a second attempt with modified titration.

Situation 3: You are within 10-15% of goal weight. The weight-loss curves for semaglutide and tirzepatide converge as patients approach lower BMI ranges. The 5.8% difference in SURMOUNT-5 was measured in patients with starting BMI of 38. In patients with BMI under 30, the difference narrows to 2-3 percentage points.

If you are starting treatment at BMI 28 with a goal of losing 20 pounds, both medications will likely get you to goal. The choice should be based on cost, injection preference, and titration speed rather than weight-loss potential.

The weight-loss advantage matters most for patients with BMI ≥35 and ambitious goals (≥20% total body weight loss). For patients with BMI 27-32 and moderate goals, the medications perform similarly.

FAQ

What is the main difference between Wegovy and Zepbound? Wegovy contains semaglutide (GLP-1 receptor agonist only). Zepbound contains tirzepatide (GLP-1 + GIP dual receptor agonist). The dual mechanism produces 3-5% more weight loss on average but also higher nausea rates. Both are once-weekly injections.

Which is more effective for weight loss, Wegovy or Zepbound? Zepbound produces modestly greater weight loss. The SURMOUNT-5 head-to-head trial showed 21.1% weight loss with tirzepatide vs 15.3% with semaglutide at 72 weeks. The difference is most pronounced in patients with BMI ≥35.

Which has worse side effects, Wegovy or Zepbound? Both have similar overall side effect rates and discontinuation rates (6-7%). Zepbound causes more moderate-to-severe nausea (22% vs 16%), but Wegovy causes more injection-site reactions (17% vs 8%). Total nausea rates are higher with Wegovy (44% vs 29%).

Can I switch from Wegovy to Zepbound or vice versa? Yes, with provider guidance. The typical approach is to start the new medication at the equivalent dose rather than re-titrating from the beginning. A rough equivalence: semaglutide 2.4 mg is approximately equivalent to tirzepatide 10-12.5 mg. Expect GI side effects to recur during the first 2-4 weeks of the switch.

Is Zepbound better than Wegovy for diabetes? Both medications improve glycemic control in patients with type 2 diabetes. Tirzepatide produces slightly greater A1C reduction (2.0% vs 1.8% average reduction in diabetes trials). For weight loss in diabetes patients, tirzepatide has a larger advantage: 15.7% vs 9.6% weight loss in SURMOUNT-2 vs STEP 2.

Does Wegovy or Zepbound work faster? Zepbound reaches therapeutic dosing faster (8 weeks vs 16 weeks), but early weight loss (first 12 weeks) is nearly identical. The weight-loss curves diverge between weeks 20 and 48, where tirzepatide sustains higher velocity.

Which is cheaper, Wegovy or Zepbound? Zepbound has a lower list price ($1,059 vs $1,349 per month), but out-of-pocket cost depends on insurance coverage and manufacturer savings programs. Compounded versions of either medication cost $297-$399 per month through platforms like FormBlends.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. Compounded versions are not FDA-approved and have not undergone the same review process. Clinical outcomes appear similar based on real-world use patterns.

Does Wegovy reduce heart attack risk better than Zepbound? Wegovy is the only medication with proven cardiovascular risk reduction in the SELECT trial (20% reduction in heart attack, stroke, and cardiovascular death). Zepbound does not yet have cardiovascular outcome data; the SURMOUNT-MMO trial results are expected in late 2026.

Can I take Wegovy and Zepbound together? No. Both medications activate the GLP-1 receptor, so combining them would increase side effects without additional benefit. Taking both together is not studied and not recommended.

How long does it take to see results with Wegovy vs Zepbound? Most patients see noticeable weight loss (5-7% total body weight) within 12-16 weeks on either medication. Maximum weight loss typically occurs at 60-72 weeks. Early response (weight loss in the first 12 weeks) predicts long-term success for both medications.

Which medication is better if I have a history of pancreatitis? Neither medication is recommended if you have a history of pancreatitis. Both GLP-1 receptor agonists carry a small increased risk of pancreatitis (0.2-0.3% vs 0.1% placebo). Discuss alternative weight-loss treatments with your provider if you have prior pancreatitis.

Will insurance cover Wegovy or Zepbound? Coverage varies by plan. Wegovy has broader Medicare coverage due to its cardiovascular indication. Commercial insurance covers either medication for obesity in approximately 40-45% of plans as of 2026, typically requiring prior authorization and BMI ≥30 (or ≥27 with comorbidities).

What happens if I stop taking Wegovy or Zepbound? Weight regain is common after discontinuation. The STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping semaglutide. Tirzepatide discontinuation data shows similar patterns. Both medications are intended for long-term use.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-2). New England Journal of Medicine. 2023.
4. Garvey WT et al. Two-year effects of tirzepatide versus semaglutide in obesity (SURMOUNT-5). Lancet. 2024.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021.
7. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023.
8. Gastaldelli A et al. Effect of tirzepatide versus semaglutide on body composition in SURMOUNT-1. Diabetes Care. 2023.
9. Heise T et al. Effects of tirzepatide versus semaglutide on energy expenditure in obesity. Obesity. 2023.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). Journal of the American Medical Association. 2021.
11. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). Journal of the American Medical Association. 2024.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
14. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.